Patient-Ventilator Interactions in Chronic Obstructive Pulmonary Diseases (COPD) Under Non-Invasive Ventilation
Launched by LIGUE PULMONAIRE GENEVOISE · Aug 11, 2010
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
Patients under NIV for hypercapnic COPD have several reasons to develop patient-ventilatory asynchrony: delayed cycling, and insufficient expiratory time may induce progressive dynamic hyperinflation, and increase intrinsic positive end-expiratory pressure (PEEPi); too high levels of pressure support may also contribute to dynamic hyperinflation. Increase in PEEPi is associated with two respiratory events: unrewarded inspiratory efforts, and auto-triggering.
Our hypotheses are: 1/that these events occur frequently in COPD under NIV and that they are not detected by medical history or usual...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • COPD, with chronic hypercapnic respiratory failure, treated by NIV, in stable clinical condition, aged above 18 years
- Exclusion Criteria:
- • Unstable clinical condition
About Ligue Pulmonaire Genevoise
Ligue Pulmonaire Genevoise (LPG) is a prominent Swiss organization dedicated to improving respiratory health through research, education, and advocacy. As a clinical trial sponsor, LPG focuses on advancing innovative therapeutic strategies and interventions for pulmonary diseases, with a commitment to enhancing patient outcomes and quality of life. The organization collaborates with healthcare professionals, academic institutions, and industry partners to conduct rigorous clinical research, ensuring adherence to ethical standards and regulatory requirements. Through its initiatives, LPG strives to foster awareness and support for lung health within the community and contribute to the global body of knowledge in pulmonology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Geneva 14, Geneva, Switzerland
Geneva 11, Geneva, Switzerland
Patients applied
Trial Officials
Jean-Paul Janssens, MD
Study Director
Division of Pulmonary Diseases; Geneva University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials